Home / Recalls / Fagron Compounding Services / D-0439-2026

D-0439-2026 Class II Ongoing

Recalled by Fagron Compounding Services — Wichita, KS

Recall Details

Product Type: Drugs
Report Date: April 15, 2026
Initiation Date: March 20, 2026
Termination Date: N/A
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 5140 bags

Product Description

norepinephrine Bitartrate, 32mg per 250mL 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5027-02

Reason for Recall

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Distribution Pattern

Nationwide in the U.S.A.

Code Information

Lot: C274-000050004, Exp.: 4/24/2026; C274-000050295, Exp.:5/8/2026; C274-000050773, Exp.: 6/4/2026; C274-000051219, Exp.: 6/21/2026; C274-000051318, Exp.: 6/27/2026; C274-000051602, Exp.: 7/12/2026.

Other recalls by Fagron Compounding Services

D-0440-2026 Class II — Vancomycin HCI, 1.25 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, (March 20, 2026)
D-0441-2026 Class II — Vancomycin HCI, 1.5 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, F (March 20, 2026)
D-0442-2026 Class II — Vancomycin HCL, 1 gram added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagr (March 20, 2026)
D-0438-2026 Class II — norepinephrine Bitartrate,16mg per 250mL 0.9% Sodium Chloride Injection USP, Fag (March 20, 2026)
D-0221-2026 Class II — Tropicamide 1%/Cyclopentolate 1%/Phenylephrine 2.5%/Ketorolac 0.5% Topical Ophth (November 20, 2025)
D-0646-2025 Class II — bevacizumab (Avastin) Injection, 1.25mg/0.05mL (0.12 mL Fill), Sterile Single-Do (August 29, 2025)
D-0225-2025 Class II — fentaNYL Citrate In Sodium Chloride 1600mcg/100mL (16 mcg per mL) CII, Single us (January 31, 2025)
D-0636-2024 Class II — Lidocaine HCl Injection, 2% (20mg per mL) (100 mg per 5 mL) per syringe, Rx only (August 15, 2024)
D-0125-2024 Class III — Tropicamide 1% (10mg/mL), Cyclopentolate 1% (10mg/mL), Phenylephrine 2.5% (25mg/ (November 10, 2023)